A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.

Key facts

Study ID

NCT06630117

Run by

Merck Sharp & Dohme LLC

People needed

245

Starts

2024-03-01

Expected to finish

2025-10-17

Last updated by the study team

2025-11-03

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is in good health prior to randomization
• Is an individual from 18 to 49 years of age inclusive or from 60 to 79 years of age inclusive

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• Has a history of myocarditis, pericarditis, and/or myopericarditis
• Has a history of cancer

Where it is running

• California Clinical Trials Medical Group managed by PAREXEL ( Site 0002) — Glendale, California, United States
• Velocity Clinical Research, Hallandale Beach ( Site 0003) — Hallandale, Florida, United States
• Research Centers of America ( Hollywood ) ( Site 0004) — Hollywood, Florida, United States
• QPS-MRA, LLC-Early Phase ( Site 0006) — South Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.